Evaluation of Anti-inflammatory Activity after Treatment with the Biofield Energy Treated Proprietary Test Formulation on Combination of Cecal Slurry, LPS and E. Coli Induced Systemic Inflammatory Response Syndrome (SIRS) in Sprague Dawley Rats
Authors: Jana Snehasis 
Published: December 2023

The aim of this study was to evaluate the anti-inflammatory response of the Biofield Energy Treated Proprietary Test Formulation and Biofield Energy Treatment per se to the animals on Cecal Slurry, LPS and E. coli-induced systemic inflammatory response syndrome (SIRS) model in Sprague Dawley rats using serum inflammatory biomarkers. In this experiment, various inflammatory biomarkers such as monokine induced by gamma interferon (MIG), regulated on activation, normal T cell expressed and secreted (RANTES), macrophage inflammatory protein-2 (MIP-2), matrix metallopeptidase 9 (MMP-9), troponin-1, procalcitonin, fibrinogen degradation product (FDP) were analysed using ELISA assay. A test formulation was formulated including minerals (magnesium, zinc, calcium, selenium, and iron), vitamins (ascorbic acid, pyridoxine HCl, vitamin E, cyanocobalamin, and cholecalciferol), Panax ginseng extract, β-carotene, and cannabidiol isolate. The constituents of the test formulation were divided into two parts; one section was defined as the untreated test formulation, while the other portion of the test formulation and three group of animals received Biofield Energy Healing Treatment remotely for about 3 minutes by a renowned Biofield Energy Healer, Mr. Mahendra Kumar Trivedi. The results showed that the level of MIG was significantly (p≤0.01) reduced by 48.57%, 56.14%, 47.95%, 51.92%, and 47.83% in the G5 (Cecal Slurry, LPS and E. coli along with the Biofield Energy Treated test formulation); G6 (Cecal Slurry, LPS and E. coli along with Biofield Energy Treatment per se to animals from day -15); G7 (Cecal Slurry, LPS and E. coli along with the Biofield Energy Treated test formulation from day -15); G8 (Cecal Slurry, LPS and E. coli along with Biofield Energy Treatment per se plus the Biofield Energy Treated test formulation from day -15), and G9 (Cecal Slurry, LPS and E. coli along with Biofield Energy Treatment per se animals plus the untreated test formulation) groups, respectively as compared to the disease control (G2) group. Additionally, the level of regulated on activation, normal T cell expressed and secreted (RANTES) was significantly (p≤0.001) decreased by 47.35%, 46.32%, 40.73%, 50.47%, and 39.96% in the G5, G6, G7, G8, and G9 groups, respectively as compared to the G2 group. The level of macrophage inflammatory protein-2 (MIP-2) was significantly (p≤0.001) decreased by 91.74%, 93.54%, 92.70%, 94.46%, and 93.80% in the G5, G6, G7, G8, and G9 groups, as compared to the G2 group. The level of MMP-9 was significantly (p≤0.001) decreased by 18.74%, 35.54%, 26.48%, 38.16%, and 22.52% in the G5, G6, G7, G8, and G9 groups, respectively as compared to the G2 group. Moreover, the level of troponin-1 was decreased by 28.53%, 28.50%, 14.14%, 30.68%, and 36.34% in the G5, G6, G7, G8, and G9 groups, respectively as compared to the untreated test formulation (G4) group. Additionally, the level of procalcitonin was significantly (p≤0.001) decreased by 27.27%, 51.73%, 46.40%, 54.65%, and 39.08% in the G5, G6, G7, G8, and G9 groups, respectively as compared to the G2 group. Further, the level of fibrinogen degradation product (FDP) was significantly (p≤0.001) decreased by 66.7%, 62.5%, 31.5%, 51.6% and 40.1% in the G5, G6, G7, G8, and G9 groups, respectively as compared to the G2 group. Overall, the data suggested anti-inflammatory potentials of the Biofield Energy Treated test formulation and Biofield Energy Treatment per se along with preventive measure on the animal with respect to various inflammatory conditions that might be beneficial various types of systemic inflammatory disorders specially sepsis, trauma, septic shock or any types of injuries. Therefore, the results showed the significant slowdown the inflammation-related disease progression and its complications/symptoms in the preventive Biofield Energy Treatment group per se and/or Biofield Energy Treated Test formulation groups (viz. G6, G7, G8, and G9) comparatively with the disease control group.